Successful Implementation of Nirsevimab and Factors Influencing Uptake in Neonatal Care
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To describe the implementation of nirsevimab for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in a pediatric hospital, focusing on strategies to ensure equitable access and address logistic challenges. Additionally, we aimed to identify predictors of nirsevimab deferral among eligible infants. METHODS: Our hospital implemented a universal immunization campaign to all eligible infants, including those discharged from the newborn nursery, intermediate care nursery, and neonatal intensive care unit. We identified key drivers and barriers, formed a multidisciplinary team, and applied a systematic approach for integration of nirsevimab orders into existing workflows. We developed and disseminated educational resources for staff and caregivers. After the implementation, we conducted univariable and multivariable analyses to identify predictors of nirsevimab deferral to evaluate implementation success and possible gaps. RESULTS: Despite challenges, we offered nirsevimab to 99% of eligible infants prior to discharge from the newborn nursery, intermediate care nursery, and neonatal intensive care unit with 71% receiving the immunization. On the multivariable analysis, independent predictors of nirsevimab deferral included preferred language of English, deferral of hepatitis B vaccine, discharge from the newborn nursery, and public insurance. CONCLUSIONS: Our implementation strategy ensured equitable access to nirsevimab for newborns with both our high uptake and acceptance rate underscoring the effectiveness of our approach. Key strategies for success included early stakeholder engagement, multidisciplinary collaboration, and proactive logistic planning. Our approach serves as a model for other institutions to offer nirsevimab prior to hospital discharge and highlights the importance of addressing both clinical and socioeconomic barriers.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Successful Implementation of Nirsevimab and Factors Influencing Uptake in Neonatal Care
- Date Crossref
- 28/01/2025
- Éditeur
- American Academy of Pediatrics (AAP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Lucile Packard Children's Hospital pays non établi dans la noticeÉtablissement de santé
-
Stanford University pays non établi dans la noticeUniversité ou école supérieure
-
a Lucille Packard Children's Hospital Stanford pays non établi dans la noticeÉtablissement de santé
-
School of Medicine Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
Lucile Packard Children's Hospital, Stanford University et a Lucille Packard Children's Hospital Stanford, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.